Previous 10 | Next 10 |
2024-06-04 10:26:59 ET More on Bristol-Myers Squibb Company Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be...
2024-06-04 09:00:00 ET Summary Bristol-Myers Squibb has experienced significant declines in its stock price, but I believe it has potential for future growth. The risks of investing in BMY include underperformance compared to the market and potential setbacks in its drug pipeline....
2024-06-03 04:06:40 ET Summary S&P 500 operating EPS growth was solid at 6.4% in Q1, but critics argue that excluding profits from top tech stocks shows less impressive growth. Bristol-Myers Squibb faces a soft growth outlook, but high expected free cash flow and steady sales ...
2024-06-02 14:00:00 ET PD-1/PD-L1 inhibitors, some of the most commonly used cancer therapies, achieved $52B in spending worldwide in 2023, a number expected to reach $90B in 2028. Examples include Merck's ( NYSE: MRK ) Keytruda (pembrolizumab), Bristol Myers Squibb's ( NYSE: BM...
2024-06-01 09:00:00 ET Summary This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks ...
2024-06-01 08:53:44 ET More on Bristol-Myers Squibb Company Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-...
First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with KRAZATI compared to standard of care chemotherapy Late-breaking data featured in an oral presentation at the 2024 Ameri...
2024-05-31 16:31:58 ET More on Immunocore Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M Cantor sees strong year ahead for oncology M&A Seeking Alpha’s Quant Rating on Immunocore Historical earnings data for Immuno...
2024-05-31 12:19:46 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis reports positive Phase 3 data for remibrutinib for chronic hives Novartis end...
2024-05-30 12:22:21 ET More on Bristol-Myers Squibb Company Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...